EP3056492A1 — Megumine salt and crystalline forms thereof of a drug (delafloxacin)
Assigned to AbbVie Inc · Expires 2016-08-17 · 10y expired
What this patent protects
A crystalline form of D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7 -(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate (salt) as anitbacterial drug, ways to make it, compositions containing it and methods of treat…
USPTO Abstract
A crystalline form of D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7 -(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate (salt) as anitbacterial drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.